<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
<front>
<journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="pmc">ploscomp</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="publisher-id">10-PLCB-RA-2352R2</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1001022</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Computational Biology/Comparative Sequence Analysis</subject><subject>Computer Science/Applications</subject><subject>Evolutionary Biology/Bioinformatics</subject><subject>Infectious Diseases/HIV Infection and AIDS</subject><subject>Virology/Mechanisms of Resistance and Susceptibility, including Host Genetics</subject></subj-group></article-categories><title-group><article-title>The Evolutionary Analysis of Emerging Low Frequency HIV-1 CXCR4 Using Variants through Time—An Ultra-Deep Approach</article-title><alt-title alt-title-type="running-head">Software for Temporal Ultra-Deep Sequence Data</alt-title></title-group><contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Archer</surname><given-names>John</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Rambaut</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Taillon</surname><given-names>Bruce E.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Harrigan</surname><given-names>P. Richard</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lewis</surname><given-names>Marilyn</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Robertson</surname><given-names>David L.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
</contrib-group><aff id="aff1"><label>1</label><addr-line>Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom</addr-line>       </aff><aff id="aff2"><label>2</label><addr-line>Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, United Kingdom</addr-line>       </aff><aff id="aff3"><label>3</label><addr-line>454 Life Sciences, Branford, Connecticut, United States of America</addr-line>       </aff><aff id="aff4"><label>4</label><addr-line>British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada</addr-line>       </aff><aff id="aff5"><label>5</label><addr-line>Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada</addr-line>       </aff><aff id="aff6"><label>6</label><addr-line>Pfizer Global Research and Development, Sandwich, United Kingdom</addr-line>       </aff><contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Kosakovsky Pond</surname><given-names>Sergei L.</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group><aff id="edit1">University of California San Diego, United States of America</aff><author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">david.robertson@manchester.ac.uk</email></corresp>
<fn fn-type="con"><p>Conceived and designed the experiments: ML DLR. Performed the experiments: JA BET PRH. Analyzed the data: JA DLR. Contributed reagents/materials/analysis tools: AR. Wrote the paper: JA ML DLR.</p></fn>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn></author-notes><pub-date pub-type="collection"><month>12</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>16</day><month>12</month><year>2010</year></pub-date><volume>6</volume><issue>12</issue><elocation-id>e1001022</elocation-id><history>
<date date-type="received"><day>8</day><month>6</month><year>2010</year></date>
<date date-type="accepted"><day>1</day><month>11</month><year>2010</year></date>
</history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2010</copyright-year><copyright-holder>Archer et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract>
<p>Large-scale parallel pyrosequencing produces unprecedented quantities of sequence data. However, when generated from viral populations current mapping software is inadequate for dealing with the high levels of variation present, resulting in the potential for biased data loss. In order to apply the 454 Life Sciences' pyrosequencing system to the study of viral populations, we have developed software for the processing of highly variable sequence data. Here we demonstrate our software by analyzing two temporally sampled HIV-1 intra-patient datasets from a clinical study of maraviroc. This drug binds the CCR5 coreceptor, thus preventing HIV-1 infection of the cell. The objective is to determine viral tropism (CCR5 versus CXCR4 usage) and track the evolution of minority CXCR4-using variants that may limit the response to a maraviroc-containing treatment regimen. Five time points (two prior to treatment) were available from each patient. We first quantify the effects of divergence on initial read k-mer mapping and demonstrate the importance of utilizing population-specific template sequences in relation to the analysis of next-generation sequence data. Then, in conjunction with coreceptor prediction algorithms that infer HIV tropism, our software was used to quantify the viral population structure pre- and post-treatment. In both cases, low frequency CXCR4-using variants (2.5–15%) were detected prior to treatment. Following phylogenetic inference, these variants were observed to exist as distinct lineages that were maintained through time. Our analysis, thus confirms the role of pre-existing CXCR4-using virus in the emergence of maraviroc-insensitive HIV. The software will have utility for the study of intra-host viral diversity and evolution of other fast evolving viruses, and is available from <ext-link ext-link-type="uri" xlink:href="http://www.bioinf.manchester.ac.uk/segminator/" xlink:type="simple">http://www.bioinf.manchester.ac.uk/segminator/</ext-link>.</p>
</abstract><abstract abstract-type="summary"><title>Author Summary</title>
<p>Due to high data volumes, error rates, and short sequence lengths, new sequencing technologies present a new challenge for computational biology. In addition, high-depth (or ultra-deep) datasets, for example from pathogens, contain exceptionally large amounts of variation over short genomes or genomic regions. Here we present software for the processing and downstream analysis of such short-read viral sequence data. We apply the software to the analysis of two HIV-1 infected individuals who did not respond optimally to the drug maraviroc. For each patient, pyrosequence data was available for five time points. In both cases we detect distinct clusters of low-frequency drug-insensitive variants that were present prior to maraviroc treatment and effectively unmasked by the removal of the drug-sensitive HIV.</p>
</abstract><funding-group><funding-statement>JA carried out this work while supported by Pfizer Global R&amp;D. The project was a collaboration with Marilyn Lewis (one of the authors) at Pfizer Global R&amp;D, and she had a role in study design, data collection and analysis, decision to publish, and preparation of the manuscript. Thanks also to the BBSRC (grant BB/H012419/1) and the Apple Research &amp; Technology Support programme for funding. They had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="11"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Sequencing platforms, such as the 454 Life Sciences' GS-FLX pyrosequencing system, has greatly parallelized the determination of nucleotide order within genetic material, resulting in the ability to produce extremely large datasets <xref ref-type="bibr" rid="pcbi.1001022-Margulies1">[1]</xref>. The vast numbers of short sequence segments produced (termed reads) in conjunction with intrinsic error rates associated with the sequencing platform <xref ref-type="bibr" rid="pcbi.1001022-Brockman1">[2]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Wang1">[3]</xref> pose challenging computational problems <xref ref-type="bibr" rid="pcbi.1001022-Pop1">[4]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Shendure1">[5]</xref>. Importantly, these data have the potential to provide previously unprecedented insight into the extent of pathogen variation (diversity) that exists within a single individual. This is particularly important in the detection of minority variants, for example, those associated with drug resistance <xref ref-type="bibr" rid="pcbi.1001022-Archer1">[6]</xref>–<xref ref-type="bibr" rid="pcbi.1001022-Tsibris1">[11]</xref>.</p>
<p>To date, software has focused on eukaryotic and prokaryotic genome-scale sequencing with its associated megabase reference genomes and vast quantities of read data <xref ref-type="bibr" rid="pcbi.1001022-Shendure1">[5]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Li1">[12]</xref>. For such studies traditional fast alignment algorithms <xref ref-type="bibr" rid="pcbi.1001022-Altschul1">[13]</xref>–<xref ref-type="bibr" rid="pcbi.1001022-Kent1">[15]</xref> that employ flexible k-mer matching are not capable of mapping reads to a reference sequence within a reasonable time. Consequently new software tools have been developed that incorporate faster string matching techniques at the expense of dealing with variation <xref ref-type="bibr" rid="pcbi.1001022-Li1">[12]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Homer1">[16]</xref>–<xref ref-type="bibr" rid="pcbi.1001022-Rumble1">[18]</xref>. For highly variable genomes this limitation will result in data loss as reads with more than the specified numbers of mismatches, in relation to a template sequence, are discarded. This loss can occur non-randomly with reads representing minority subpopulations being less likely to be mapped to the template. For example, two distinct phenotypes of HIV-1 exist that are defined by the host coreceptor that is used during cell entry. The coreceptors involved are chemokine (C–C motif) receptor 5 (CCR5) and chemokine (C-X-C) receptor 4 (CXCR4). The location of the viral genome that determines the phenotype is the third variable (V3) loop, a highly variable region <xref ref-type="bibr" rid="pcbi.1001022-Starcich1">[19]</xref> located within HIV's envelope gene, <italic>env</italic> <xref ref-type="bibr" rid="pcbi.1001022-Bjorndal1">[20]</xref>–<xref ref-type="bibr" rid="pcbi.1001022-Koot1">[22]</xref>. The most often used genomic reference sequence for HIV-1 is HXB2, a CXCR4-using virus. When mapping V3 data to HXB2, and limiting the number of mismatches allowed, reads representing CCR5 variants are more likely to be lost during mapping as a result of known amino acid changes associated with that phenotype <xref ref-type="bibr" rid="pcbi.1001022-Cardozo1">[23]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Jensen1">[24]</xref>. This may result in a misleading ratio of coreceptor use within an HIV-1 population, which can have consequences for drug treatment decisions <xref ref-type="bibr" rid="pcbi.1001022-Soriano1">[25]</xref>. Thus, for rapidly evolving viruses, such as HIV-1 <xref ref-type="bibr" rid="pcbi.1001022-Jetzt1">[26]</xref>–<xref ref-type="bibr" rid="pcbi.1001022-Wei1">[29]</xref>, a limitation on the number of mismatches tolerated during read mapping is less than optimal. Modification of traditional k-mer matching approaches <xref ref-type="bibr" rid="pcbi.1001022-Altschul1">[13]</xref> is a more suitable approach and becomes scalable (due to the smaller genome sizes) as they allow for increased tolerance when dealing with higher levels of variation in viral 454 data <xref ref-type="bibr" rid="pcbi.1001022-Archer1">[6]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Tsibris1">[11]</xref>.</p>
<p>Prior to any evolutionary study reads must be accurately mapped and aligned. Our software performs these tasks as well as subsequent tropism testing, phylogenetic tree inference and visualization (<xref ref-type="fig" rid="pcbi-1001022-g001">Fig. 1</xref>). We demonstrate the software's underlying framework in order to quantify the effects of divergence on the mapping of reads to a template sequence. In addition to unbiased mapping of data, a reduction of divergence between reads and template is favorable for the removal of platform dependent insertions. Characteristically with 454 data there is a high rate of insertion error associated with the chemistry involved during the pyrosequencing process <xref ref-type="bibr" rid="pcbi.1001022-Brockman1">[2]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Wang1">[3]</xref>. Failure to remove such insertions can result in a further loss of usable data when translations are required during downstream analysis.</p>
<fig id="pcbi-1001022-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001022.g001</object-id><label>Figure 1</label><caption>
<title>The data analysis framework.</title>
<p>On the left hand side the preprocessing of the template sequence prior to read mapping is illustrated. The fragments titled “k-mers” are all the unique words (length = 5) within the template sequence. These are stored along with their corresponding locations. On the opposite side all k-mers of equal length, extracted from the read, are shown. The plot indicates the frequency of k-mer matches across the template sequence for a single read. Grey boxes indicate processing events that take place within the framework. The yellow circles indicate optimization steps: (i) only exact k-mer matches used (ii) a heuristic alignment not constructed from the k-mer matching (just the k-mer match frequencies are plotted) and (iii) only the appropriate region of the template is pairwise aligned to the read.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001022.g001" xlink:type="simple"/></fig>
<p>We apply our software to temporally sampled 454 datasets from two HIV-1 infected individuals in order to characterize the emergence of low frequency CXCR4-using variants following treatment with an HIV entry-inhibitor drug, the CCR5 antagonist maraviroc. As the drug will not directly impact on viruses using the CXCR4 coreceptor <xref ref-type="bibr" rid="pcbi.1001022-Dorr1">[30]</xref>, patients are screened for their presence prior to treatment <xref ref-type="bibr" rid="pcbi.1001022-Soriano1">[25]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Cooper1">[31]</xref>. The aim is to distinguish a viral population that is exclusively CCR5 tropic (R5) from a viral population including either dual-mixed, DM, (R5 and exclusively CXCR4-using [X4]), or R5 and dual-tropic viruses (those that can use both CCR5 and CXCR4 [R5X4]). Note, we refer to both X4 and R5X4 tropic viruses as CXCR4-using. This application of our software demonstrates that sequence data generated from the 454 platform – in conjunction with coreceptor prediction tests based on HIV's V3 region <xref ref-type="bibr" rid="pcbi.1001022-Cardozo1">[23]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Jensen1">[24]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Rosen1">[32]</xref> – permits the quantification and evolutionary analysis of HIV-1 tropism present at low frequencies within a sample more effectively than could be achieved using standard population sequencing technologies <xref ref-type="bibr" rid="pcbi.1001022-Archer1">[6]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Tsibris1">[11]</xref>. Our software will also have utility for studying the within-host diversity of other fast evolving viruses.</p>
</sec><sec id="s2" sec-type="methods">
<title>Methods</title>
<sec id="s2a">
<title>Datasets</title>
<p>Samples for pyrosequencing were obtained from two HIV-1 infected males, patients D and E, both of whom were treatment naïve and enrolled in the QD arm of the A4001026 study <xref ref-type="bibr" rid="pcbi.1001022-Cooper1">[31]</xref>, were infected with subtype B virus and received maraviroc once daily together with zidovudine and lamivudine. They discontinued the study due to insufficient clinical response: patient D continued to week 2 and patient E to week 24. Both had the M184V mutation in reverse transcriptase at failure, which confers resistance to the background therapy and, in addition, patient D had M41M/L and K70K/R. Samples were collected over five time points: screening (40 days before), day 1, week 2 (day 15), week 12 (day 80) and week 16 (day 107) for patient D and screening (41 days before), day 1, week 8 (day 57), week 24 (day 162) and week 30 (day 211) for patient E.</p>
<p>For each sample, RNA extraction and amplification from the gp120 region of <italic>env</italic> was performed. The amplicons were subjected to nebulization to generate fragments of approximately 600 nucleotides. These were amplified as described in Margulies <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1001022-Margulies1">[1]</xref>. and sequenced on the Genome Sequencer 20 (GS20, Roche Applied Sciences). Standard protocols for the generation of a library of tagged single-stranded DNA molecules were used (for details, see Margulies <italic>et al.</italic> <xref ref-type="bibr" rid="pcbi.1001022-Margulies1">[1]</xref>). The GS20 software package was used to generate the sequence files. This resulted in files containing between 14,000 and 31,000 reads (<xref ref-type="table" rid="pcbi-1001022-t001">Table 1</xref>). The data is available at the NCBI Sequence Read Archive (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/Traces/sra" xlink:type="simple">http://www.ncbi.nlm.nih.gov/Traces/sra</ext-link>) under accession number SRA023641.1.</p>
<table-wrap id="pcbi-1001022-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001022.t001</object-id><label>Table 1</label><caption>
<title>Read extraction comparison.</title>
</caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1001022-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001022.t001" xlink:type="simple"/><table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" colspan="1" rowspan="1">Time point</td>
<td align="left" colspan="1" rowspan="1">No. of reads across entire gp120</td>
<td align="left" colspan="1" rowspan="1">No. of reads mapped to a dataset-specific consensus across V3</td>
<td align="left" colspan="1" rowspan="1">No. of reads mapped to HXB2's V3 region</td>
<td align="left" colspan="1" rowspan="1">Difference between dataset-specific consensus and HXB2 mapping</td>
<td align="left" colspan="1" rowspan="1">% data lost using HXB2</td>
<td align="left" colspan="1" rowspan="1">Divergence between templates (hamming)</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="7" rowspan="1"><bold>Patient D</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Screening</bold></td>
<td align="left" colspan="1" rowspan="1">30,686</td>
<td align="left" colspan="1" rowspan="1">8,385</td>
<td align="left" colspan="1" rowspan="1">6,309</td>
<td align="left" colspan="1" rowspan="1">2,076</td>
<td align="left" colspan="1" rowspan="1">24.8</td>
<td align="left" colspan="1" rowspan="1">0.1369</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Day 1</bold></td>
<td align="left" colspan="1" rowspan="1">28,902</td>
<td align="left" colspan="1" rowspan="1">8,655</td>
<td align="left" colspan="1" rowspan="1">6,438</td>
<td align="left" colspan="1" rowspan="1">2,217</td>
<td align="left" colspan="1" rowspan="1">25.6</td>
<td align="left" colspan="1" rowspan="1">0.1369</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Week 2</bold></td>
<td align="left" colspan="1" rowspan="1">28,521</td>
<td align="left" colspan="1" rowspan="1">8,009</td>
<td align="left" colspan="1" rowspan="1">5,679</td>
<td align="left" colspan="1" rowspan="1">2,330</td>
<td align="left" colspan="1" rowspan="1">29.1</td>
<td align="left" colspan="1" rowspan="1">0.1320</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Week 12</bold></td>
<td align="left" colspan="1" rowspan="1">23,312</td>
<td align="left" colspan="1" rowspan="1">6,845</td>
<td align="left" colspan="1" rowspan="1">5,076</td>
<td align="left" colspan="1" rowspan="1">1,769</td>
<td align="left" colspan="1" rowspan="1">25.8</td>
<td align="left" colspan="1" rowspan="1">0.1393</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Week 16</bold></td>
<td align="left" colspan="1" rowspan="1">14,880</td>
<td align="left" colspan="1" rowspan="1">3,591</td>
<td align="left" colspan="1" rowspan="1">2,669</td>
<td align="left" colspan="1" rowspan="1">922</td>
<td align="left" colspan="1" rowspan="1">25.7</td>
<td align="left" colspan="1" rowspan="1">0.1589</td>
</tr>
<tr>
<td align="left" colspan="7" rowspan="1"><bold>Patient E</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Screening</bold></td>
<td align="left" colspan="1" rowspan="1">12,646</td>
<td align="left" colspan="1" rowspan="1">3,257</td>
<td align="left" colspan="1" rowspan="1">1,813</td>
<td align="left" colspan="1" rowspan="1">1,444</td>
<td align="left" colspan="1" rowspan="1">44.3</td>
<td align="left" colspan="1" rowspan="1">0.1736</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Day 1</bold></td>
<td align="left" colspan="1" rowspan="1">18,381</td>
<td align="left" colspan="1" rowspan="1">4,386</td>
<td align="left" colspan="1" rowspan="1">2,891</td>
<td align="left" colspan="1" rowspan="1">1,495</td>
<td align="left" colspan="1" rowspan="1">34.1</td>
<td align="left" colspan="1" rowspan="1">0.1589</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Week 8</bold></td>
<td align="left" colspan="1" rowspan="1">18,551</td>
<td align="left" colspan="1" rowspan="1">4,085</td>
<td align="left" colspan="1" rowspan="1">2,611</td>
<td align="left" colspan="1" rowspan="1">1,474</td>
<td align="left" colspan="1" rowspan="1">36.1</td>
<td align="left" colspan="1" rowspan="1">0.1418</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Week 24</bold></td>
<td align="left" colspan="1" rowspan="1">19,268</td>
<td align="left" colspan="1" rowspan="1">4,723</td>
<td align="left" colspan="1" rowspan="1">3,228</td>
<td align="left" colspan="1" rowspan="1">1,495</td>
<td align="left" colspan="1" rowspan="1">31.7</td>
<td align="left" colspan="1" rowspan="1">0.1840</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Week 30</bold></td>
<td align="left" colspan="1" rowspan="1">17,993</td>
<td align="left" colspan="1" rowspan="1">4,764</td>
<td align="left" colspan="1" rowspan="1">2,890</td>
<td align="left" colspan="1" rowspan="1">1,874</td>
<td align="left" colspan="1" rowspan="1">39.3</td>
<td align="left" colspan="1" rowspan="1">0.1711</td>
</tr>
</tbody>
</table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Comparison of the number of reads extracted at each time point for patients D and E using k-mer mapping for a dataset-specific consensus and HXB2 templates. The genome coordinates 6900 to 7305 were used so as to include the V3 region and all reads spanning V3. The numbers in the first column are the total number of reads covering gp120.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2b">
<title>K-mer mapping</title>
<p>Although RNA extraction and amplification was carried out across the entire gp120 gene, the region that is required for the coreceptor prediction of HIV-1 variants is V3 <xref ref-type="bibr" rid="pcbi.1001022-Cardozo1">[23]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Jensen1">[24]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Rosen1">[32]</xref>. Reads covering this region were identified using a k-mer matching process similar to the initial phase of the BLAST algorithm <xref ref-type="bibr" rid="pcbi.1001022-Altschul1">[13]</xref>. For a single read the location of all k-mers of size five are identified across the template sequence. If a matching region is found for the read, the frequencies of k-mer hits will be above the random level of background noise at that location (<xref ref-type="fig" rid="pcbi-1001022-g001">Fig. 1</xref>). For each dataset the coordinates of the template in relation to the HXB2 reference genome are 6900 to 7305. This accommodates longer reads that may span the entire V3 region. The coordinates of the V3 loop within this region are 7110 to 7217. Dataset specificity was generated within the templates using a pre-mapping to the HXB2 reference sequence for which multiple alignments are then generated within windows of size 70 (using a 20 nucleotide overlap). Within each of these alignments columns containing more than 50% gaps were removed. Consensus sequences, created for each alignment, are then appended in order to form data-specific templates to which reads are then remapped.</p>
<p>To explore the effects of using a consensus template on k-mer mapping, for each dataset, we compared the number of reads mapped to the data-specific template for that dataset to the number of reads mapped using HXB2 – the latter being the pre-mapping stage prior to consensus template generation. Next, we took our patient D screening dataset and introduced random variation into the consensus template in sequential steps of 2, 4 up to 26% (50 repetitions for each). After each introduction of random variation, the k-mer mapping was performed and the number of reads successfully mapped recorded. It should be noted that no precise pairwise alignment to the template sequence is generated during k-mer mapping. Instead the reads within our datasets covering the portion of the HIV-1 genome between the coordinates 6900 to 7305 are identified along with their approximate start positions. The k-mer mapping approach implicitly allows for a higher degree of tolerance in identifying such reads when compared to approaches that limit the number of mismatches <xref ref-type="bibr" rid="pcbi.1001022-Li1">[12]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Homer1">[16]</xref>–<xref ref-type="bibr" rid="pcbi.1001022-Rumble1">[18]</xref> as, although the process involves matching exact k-mers to the template at any given location, the overall frequency of k-mer hits will increase at the most likely location of the read across the template (<xref ref-type="fig" rid="pcbi-1001022-g001">Fig. 1</xref>). This approach, thus, does not specify an exact limitation on the number of mismatches allowed between the read itself and the template.</p>
</sec><sec id="s2c">
<title>Pairwise alignment</title>
<p>Following k-mer mapping, reads are pairwise aligned to the consensus template using Smith and Waterman <xref ref-type="bibr" rid="pcbi.1001022-Smith1">[33]</xref>. Indices obtained during k-mer mapping are used to optimize the process by only aligning reads to the appropriate region. Platform dependent insertion error, which makes up the majority of non-biological error <xref ref-type="bibr" rid="pcbi.1001022-Brockman1">[2]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Wang1">[3]</xref>, is accounted for by maintaining reference to the dataset specific template. Specifically, insertions relative to the template, which represents an in frame consensus sequence, are removed. The frequency at which these insertions occurred across the V3 region was recorded. The usage of a data-specific consensus sequence is important to ensure that insertions naturally existing within the population are not erroneously removed based on use of a divergent template sequence.</p>
</sec><sec id="s2d">
<title>Tropism prediction and phylogenetic inference</title>
<p>Reads spanning the V3 region of <italic>env</italic> were extracted, truncated, identical reads removed (frequencies were stored) and multiply aligned using Muscle <xref ref-type="bibr" rid="pcbi.1001022-Edgar1">[34]</xref>, packaged with the software. Coreceptor prediction was performed using the 11/24/25 “charge rule” <xref ref-type="bibr" rid="pcbi.1001022-Cardozo1">[23]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Rosen1">[32]</xref>, implemented within the software and using the PSSM web tool <xref ref-type="bibr" rid="pcbi.1001022-Jensen1">[24]</xref>. Sequence logos were generated for inferred R5 and CXCR4-using sequence present at each time point using the Web Logo tool <xref ref-type="bibr" rid="pcbi.1001022-Crooks1">[35]</xref>. Nucleotide sequences, annotated with coreceptor predictions, were used to infer evolutionary relationships by maximum likelihood using PhyML <xref ref-type="bibr" rid="pcbi.1001022-Guindon1">[36]</xref>, packaged with the software. The HKY model of sequence evolution was used. The resulting phylogenetic trees were visualized using an integrated version of CTree <xref ref-type="bibr" rid="pcbi.1001022-Archer2">[37]</xref>. Because bootstrapping is unreliable when performed on very short sequence alignments, the significance of the identified clusters within datasets representing the early time points was determined by comparing the ratio between the intra-cluster pairwise distance and the inter-cluster pairwise distance (of five random clusters) to a distribution of values obtained for 500 sets randomly assigned clusters. A low intra-cluster pairwise distance relative to the inter-cluster pairwise distance implies a robust cluster <xref ref-type="bibr" rid="pcbi.1001022-Archer3">[38]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Rambaut1">[39]</xref>. Additionally clustering significance was tested using the <italic>approximate likelihood ratio test</italic> <xref ref-type="bibr" rid="pcbi.1001022-Anisimova1">[40]</xref> for branches as implemented within PhyML.</p>
</sec><sec id="s2e">
<title>Key functions of the software</title>
<p>The pipeline used for processing the initial read data is available within our software (<xref ref-type="fig" rid="pcbi-1001022-g001">Fig. 1</xref>). Implemented in Java the executable runs on Mac OS X, Linux and Windows. All required external binaries are included within the package. The input is a FASTA formatted file containing unmapped read data. Output files are in FASTA, TXT, PDF or NEWICK format as appropriate. A summary of the key functions incorporated into the software are: (i) accurate mapping of next generation sequence data containing high amounts of variation, (ii) exportation of reads spanning user defined regions of the template, (iii) translation of reads, (iv) determination of nucleotide and/or amino acid residue frequencies, (v) generation of a consensus sequence across the entire dataset taking into account data-specific indels, thus, reducing dependency on a generic template, (vi) removal of reads based on a hamming distance from their corresponding region on the template, (vii) generation of a multiple alignment of reads spanning a particular region of the template using Muscle <xref ref-type="bibr" rid="pcbi.1001022-Edgar1">[34]</xref>, (viii) detection and annotation of low frequency variants, (ix) inference of phylogenetic trees using PhyML <xref ref-type="bibr" rid="pcbi.1001022-Guindon1">[36]</xref>, (x) tree label searching based on the annotation produced in viii and visualized using CTree <xref ref-type="bibr" rid="pcbi.1001022-Archer2">[37]</xref>, and (xi) management of bar coded data. During the scaffolding process, a number of output plots are generated to summarize the data. These include read length distributions and template coverage. The latter is portrayed in a circular plot to allow for longer templates to be displayed optimally.</p>
</sec></sec><sec id="s3">
<title>Results</title>
<sec id="s3a">
<title>K-mer mapping</title>
<p>For each dataset, following k-mer mapping to the consensus template, high read coverage was observed across the V3 region (<xref ref-type="table" rid="pcbi-1001022-t001">Table 1</xref>). In each case when HXB2 was used as a template sequence fewer reads are mapped. For patient D the mean loss of reads is 26.4%, while for patient E it is 36.5%, the difference being due to the divergence between patients D and E's data-specific templates and HXB2 (<xref ref-type="table" rid="pcbi-1001022-t001">Table 1</xref>). When random variation in sequential steps of 2 to 26% was introduced into the consensus template derived from the patient D screening dataset and k-mer mapping performed on reads from that dataset, a reduction in the number of mapped can be observed that is directly proportional to increasing divergence (<xref ref-type="fig" rid="pcbi-1001022-g002">Fig. 2</xref>).</p>
<fig id="pcbi-1001022-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001022.g002</object-id><label>Figure 2</label><caption>
<title>Relationship between k-mer mapping and diversity.</title>
<p>As divergence from the consensus template increases the number of reads successfully mapped decreases. Each box and whisker (1.5 times the inter-quartile range) represents 50 repetitions of the mapping process at the level of divergence indicated on the x-axis. The bottom circle, on the y-axis, indicates the percentage of reads mapped to HXB2 in relation to the total number mapped to the consensus template (top circle). The dataset used for this comparison was patient D at screening.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001022.g002" xlink:type="simple"/></fig></sec><sec id="s3b">
<title>Pairwise alignment</title>
<p>Reads were pairwise aligned to the appropriate region (identified from the k-mer mapping step) of the data-specific consensus templates and those spanning both the start and end of the V3 region were extracted and truncated. Between 17 and 33% of reads contain at least one insertion event across the V3 region in comparison to the consensus template (<xref ref-type="table" rid="pcbi-1001022-t002">Table 2</xref>). The vast majority of these insertions were observed to be singleton or dinucleotide insertions (causing a frame shift), with a mean per site frequency of 0.18%. Note, this frequency is after the sequences have been truncated. These are lower numbers than would be expected if complete reads had been included <xref ref-type="bibr" rid="pcbi.1001022-Wang1">[3]</xref> as the starts and ends of the majority of the reads have been removed by the truncation step. During the alignment process such insertions were removed in order to maintain as many correctly translated V3 regions as possible.</p>
<table-wrap id="pcbi-1001022-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001022.t002</object-id><label>Table 2</label><caption>
<title>V3 region coverage.</title>
</caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1001022-t002-2" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001022.t002" xlink:type="simple"/><table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" colspan="1" rowspan="1">Time point</td>
<td align="left" colspan="1" rowspan="1">No. of complete V3's initially extracted</td>
<td align="left" colspan="1" rowspan="1">No. of insertions present</td>
<td align="left" colspan="1" rowspan="1">No. of reads containing at least one insertion</td>
<td align="left" colspan="1" rowspan="1">% per site insertion frequency across the V3 region</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="5" rowspan="1"><bold>Patient D</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Screening</bold></td>
<td align="left" colspan="1" rowspan="1">2,022</td>
<td align="left" colspan="1" rowspan="1">489 (24.2%)</td>
<td align="left" colspan="1" rowspan="1">581</td>
<td align="left" colspan="1" rowspan="1">0.27</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Day 1</bold></td>
<td align="left" colspan="1" rowspan="1">2,081</td>
<td align="left" colspan="1" rowspan="1">471 (22.6%)</td>
<td align="left" colspan="1" rowspan="1">533</td>
<td align="left" colspan="1" rowspan="1">0.24</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Week 2</bold></td>
<td align="left" colspan="1" rowspan="1">2,266</td>
<td align="left" colspan="1" rowspan="1">655 (28.9%)</td>
<td align="left" colspan="1" rowspan="1">759</td>
<td align="left" colspan="1" rowspan="1">0.35</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Week 12</bold></td>
<td align="left" colspan="1" rowspan="1">1,609</td>
<td align="left" colspan="1" rowspan="1">378 (23.5%)</td>
<td align="left" colspan="1" rowspan="1">440</td>
<td align="left" colspan="1" rowspan="1">0.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Week 16</bold></td>
<td align="left" colspan="1" rowspan="1">908</td>
<td align="left" colspan="1" rowspan="1">183 (20.2%)</td>
<td align="left" colspan="1" rowspan="1">207</td>
<td align="left" colspan="1" rowspan="1">0.1</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1"><bold>Patient E</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Screening</bold></td>
<td align="left" colspan="1" rowspan="1">778</td>
<td align="left" colspan="1" rowspan="1">174 (22.4%)</td>
<td align="left" colspan="1" rowspan="1">199</td>
<td align="left" colspan="1" rowspan="1">0.1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Day 1</bold></td>
<td align="left" colspan="1" rowspan="1">1,022</td>
<td align="left" colspan="1" rowspan="1">180 (17.6%)</td>
<td align="left" colspan="1" rowspan="1">216</td>
<td align="left" colspan="1" rowspan="1">0.1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Week 8</bold></td>
<td align="left" colspan="1" rowspan="1">1,082</td>
<td align="left" colspan="1" rowspan="1">352 (32.5%)</td>
<td align="left" colspan="1" rowspan="1">506</td>
<td align="left" colspan="1" rowspan="1">0.23</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Week 24</bold></td>
<td align="left" colspan="1" rowspan="1">1,015</td>
<td align="left" colspan="1" rowspan="1">253 (24.9%)</td>
<td align="left" colspan="1" rowspan="1">387</td>
<td align="left" colspan="1" rowspan="1">0.17</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold> Week 30</bold></td>
<td align="left" colspan="1" rowspan="1">1,244</td>
<td align="left" colspan="1" rowspan="1">235 (18.9%)</td>
<td align="left" colspan="1" rowspan="1">267</td>
<td align="left" colspan="1" rowspan="1">0.12</td>
</tr>
</tbody>
</table></alternatives><table-wrap-foot><fn id="nt102"><label/><p>The total number of reads completely spanning the V3 region (coordinates 7110 to 7217), regardless of the presence or absence of frame shift errors. The percentage containing singleton or dinucleotide insertion events across this region is displayed.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c">
<title>Tropism prediction and phylogenetic inference</title>
<p>For both patients a high coverage of in-frame reads across the V3 region was observed at each time point (<xref ref-type="table" rid="pcbi-1001022-t003">Tables 3</xref> and <xref ref-type="table" rid="pcbi-1001022-t004">4</xref>) with many unique variants. Those reads that could not be translated correctly were discarded, resulting in the lower numbers observed in <xref ref-type="table" rid="pcbi-1001022-t003">Tables 3</xref> and <xref ref-type="table" rid="pcbi-1001022-t004">4</xref> than those presented in <xref ref-type="table" rid="pcbi-1001022-t002">table 2</xref>. When both the charge rule and PSSM tests were performed on these data, CXCR4-using variants were detected prior to treatment within both patients (<xref ref-type="table" rid="pcbi-1001022-t003">Tables 3</xref> and <xref ref-type="table" rid="pcbi-1001022-t004">4</xref>). On maraviroc treatment, for patient D, CXCR4-using virus increased to a frequency of 41% and for patient E increased to 99% at the sampling times (<xref ref-type="table" rid="pcbi-1001022-t003">Tables 3</xref> and <xref ref-type="table" rid="pcbi-1001022-t004">4</xref>). Interestingly, despite the CXCR4-using population increasing in patient D and becoming dominant in patient E on-treatment, the reduction in viral load corresponds to an order of magnitude less CXCR4-using virus than that prior to treatment.</p>
<table-wrap id="pcbi-1001022-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001022.t003</object-id><label>Table 3</label><caption>
<title>Patient D tropism predictions.</title>
</caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1001022-t003-3" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001022.t003" xlink:type="simple"/><table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" colspan="1" rowspan="1">Time point</td>
<td align="left" colspan="1" rowspan="1">R5 (%)</td>
<td align="left" colspan="1" rowspan="1">CXCR4-using (%)</td>
<td align="left" colspan="1" rowspan="1">Viral load (copies/ml)</td>
<td align="left" colspan="1" rowspan="1">CXCR4-using viral load (copies/ml)</td>
<td align="left" colspan="1" rowspan="1">No. V3 of reads and unique reads in brackets.</td>
<td align="left" colspan="1" rowspan="1">CD4 (cells/mcl)</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>Screening</bold></td>
<td align="left" colspan="6" rowspan="1">pre-treatment with maraviroc</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Charge Rule</td>
<td align="left" colspan="1" rowspan="1">93.5</td>
<td align="left" colspan="1" rowspan="1">6.5</td>
<td align="left" colspan="1" rowspan="1">668,000</td>
<td align="left" colspan="1" rowspan="1">43,420</td>
<td align="left" colspan="1" rowspan="1">1,743 (284)</td>
<td align="left" colspan="1" rowspan="1">31</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PSSM</td>
<td align="left" colspan="1" rowspan="1">93.7</td>
<td align="left" colspan="1" rowspan="1">6.3</td>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>Day 1</bold></td>
<td align="left" colspan="6" rowspan="1">pre-treatment with maraviroc</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Charge Rule</td>
<td align="left" colspan="1" rowspan="1">86.7</td>
<td align="left" colspan="1" rowspan="1">13.3</td>
<td align="left" colspan="1" rowspan="1">673,000</td>
<td align="left" colspan="1" rowspan="1">89,509</td>
<td align="left" colspan="1" rowspan="1">1,755 (266)</td>
<td align="left" colspan="1" rowspan="1">29</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PSSM</td>
<td align="left" colspan="1" rowspan="1">86.7</td>
<td align="left" colspan="1" rowspan="1">13.3</td>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>Week 2</bold></td>
<td align="left" colspan="6" rowspan="1">on-treatment with maraviroc</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Charge Rule</td>
<td align="left" colspan="1" rowspan="1">58.7</td>
<td align="left" colspan="1" rowspan="1">41.3</td>
<td align="left" colspan="1" rowspan="1">3,560</td>
<td align="left" colspan="1" rowspan="1">1,470</td>
<td align="left" colspan="1" rowspan="1">1,897 (196)</td>
<td align="left" colspan="1" rowspan="1">88</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PSSM</td>
<td align="left" colspan="1" rowspan="1">58.8</td>
<td align="left" colspan="1" rowspan="1">41.2</td>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>Week 12</bold></td>
<td align="left" colspan="6" rowspan="1">off-treatment with maraviroc</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Charge Rule</td>
<td align="left" colspan="1" rowspan="1">82.1</td>
<td align="left" colspan="1" rowspan="1">17.9</td>
<td align="left" colspan="1" rowspan="1">25,300</td>
<td align="left" colspan="1" rowspan="1">4,528</td>
<td align="left" colspan="1" rowspan="1">1,344 (194)</td>
<td align="left" colspan="1" rowspan="1">97</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PSSM</td>
<td align="left" colspan="1" rowspan="1">82.4</td>
<td align="left" colspan="1" rowspan="1">17.6</td>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>Week 16</bold></td>
<td align="left" colspan="6" rowspan="1">off-treatment with maraviroc</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Charge Rule</td>
<td align="left" colspan="1" rowspan="1">42.7</td>
<td align="left" colspan="1" rowspan="1">57.3</td>
<td align="left" colspan="1" rowspan="1">1,890</td>
<td align="left" colspan="1" rowspan="1">1,082</td>
<td align="left" colspan="1" rowspan="1">710 (106)</td>
<td align="left" colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PSSM</td>
<td align="left" colspan="1" rowspan="1">42.7</td>
<td align="left" colspan="1" rowspan="1">57.3</td>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
</tr>
</tbody>
</table></alternatives><table-wrap-foot><fn id="nt103"><label/><p>Predicted coreceptor usage, viral load, estimated proportion of population that is CXCR4-using (from % estimated by charge rule), number of V3 sequences extracted (in-frame) and CD4 cell count at different time points pre- and post-treatment for patient D.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pcbi-1001022-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001022.t004</object-id><label>Table 4</label><caption>
<title>Patient E tropism predictions.</title>
</caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1001022-t004-4" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001022.t004" xlink:type="simple"/><table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" colspan="1" rowspan="1">Time point</td>
<td align="left" colspan="1" rowspan="1">R5 (%)</td>
<td align="left" colspan="1" rowspan="1">CXCR4-using (%)</td>
<td align="left" colspan="1" rowspan="1">Viral load (copies/ml)</td>
<td align="left" colspan="1" rowspan="1">CXCR4-using viral load (copies/ml)</td>
<td align="left" colspan="1" rowspan="1">No. V3 of reads and unique reads in brackets.</td>
<td align="left" colspan="1" rowspan="1">CD4 (cells/mcl)</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>Screening</bold></td>
<td align="left" colspan="6" rowspan="1">pre-treatment with maraviroc</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Charge Rule</td>
<td align="left" colspan="1" rowspan="1">97.5</td>
<td align="left" colspan="1" rowspan="1">2.5</td>
<td align="left" colspan="1" rowspan="1">476,000</td>
<td align="left" colspan="1" rowspan="1">11,900</td>
<td align="left" colspan="1" rowspan="1">651 (113)</td>
<td align="left" colspan="1" rowspan="1">27</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PSSM</td>
<td align="left" colspan="1" rowspan="1">97.7</td>
<td align="left" colspan="1" rowspan="1">2.3</td>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>Day 1</bold></td>
<td align="left" colspan="6" rowspan="1">pre-treatment with maraviroc</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Charge Rule</td>
<td align="left" colspan="1" rowspan="1">85</td>
<td align="left" colspan="1" rowspan="1">15</td>
<td align="left" colspan="1" rowspan="1">350,000</td>
<td align="left" colspan="1" rowspan="1">52,500</td>
<td align="left" colspan="1" rowspan="1">833 (147)</td>
<td align="left" colspan="1" rowspan="1">12</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PSSM</td>
<td align="left" colspan="1" rowspan="1">94.72</td>
<td align="left" colspan="1" rowspan="1">5.28</td>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>Week 8</bold></td>
<td align="left" colspan="6" rowspan="1">on-treatment with maraviroc</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Charge Rule</td>
<td align="left" colspan="1" rowspan="1">0.7</td>
<td align="left" colspan="1" rowspan="1">99.3</td>
<td align="left" colspan="1" rowspan="1">23,000</td>
<td align="left" colspan="1" rowspan="1">22,839</td>
<td align="left" colspan="1" rowspan="1">900 (93)</td>
<td align="left" colspan="1" rowspan="1">162</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PSSM</td>
<td align="left" colspan="1" rowspan="1">60.9</td>
<td align="left" colspan="1" rowspan="1">39.1</td>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>Week 24</bold></td>
<td align="left" colspan="6" rowspan="1">on-treatment with maraviroc</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Charge Rule</td>
<td align="left" colspan="1" rowspan="1">0.5</td>
<td align="left" colspan="1" rowspan="1">99.5</td>
<td align="left" colspan="1" rowspan="1">5,420</td>
<td align="left" colspan="1" rowspan="1">5,392</td>
<td align="left" colspan="1" rowspan="1">1123 (153)</td>
<td align="left" colspan="1" rowspan="1">176</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PSSM</td>
<td align="left" colspan="1" rowspan="1">1.4</td>
<td align="left" colspan="1" rowspan="1">98.6</td>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>Week 30</bold></td>
<td align="left" colspan="6" rowspan="1">off-treatment with maraviroc</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Charge Rule</td>
<td align="left" colspan="1" rowspan="1">0.4</td>
<td align="left" colspan="1" rowspan="1">99.6</td>
<td align="left" colspan="1" rowspan="1">85,700</td>
<td align="left" colspan="1" rowspan="1">85,357</td>
<td align="left" colspan="1" rowspan="1">1054 (126)</td>
<td align="left" colspan="1" rowspan="1">132</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PSSM</td>
<td align="left" colspan="1" rowspan="1">3.1</td>
<td align="left" colspan="1" rowspan="1">96.9</td>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
<td align="left" colspan="1" rowspan="1"/>
</tr>
</tbody>
</table></alternatives><table-wrap-foot><fn id="nt104"><label/><p>Predicted coreceptor usage, viral load, estimated proportion of population that is CXCR4-using (from % estimated by charge rule), number of V3 sequences extracted (in-frame) and CD4 cell count at different time points pre- and post-treatment for patient E.</p></fn></table-wrap-foot></table-wrap>
<p>The inference of the evolutionary history for each dataset, revealed the majority of CXCR4-using variants formed a distinct cluster, present prior to maraviroc treatment and divergent to the main R5 populations present prior to treatment (<xref ref-type="fig" rid="pcbi-1001022-g003">Fig. 3</xref> and. <xref ref-type="fig" rid="pcbi-1001022-g004">4</xref>). The inset plots confirm the significance of each CXCR4-using cluster based on the comparison of intra- and inter-pairwise distances and confirmed using the <italic>approximate likelihood ratio test</italic> (<xref ref-type="fig" rid="pcbi-1001022-g003">Fig. 3</xref> and <xref ref-type="fig" rid="pcbi-1001022-g004">4</xref>). The sequence logos beside each phylogeny represents a comparison between the sequence characteristics of the R5 tropic and CXCR4-using variants. At each time point, key differences in charge <xref ref-type="bibr" rid="pcbi.1001022-Cardozo1">[23]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Jensen1">[24]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Rosen1">[32]</xref> can be observed at sites 11 for patient D and at site 25 for patient E.</p>
<fig id="pcbi-1001022-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001022.g003</object-id><label>Figure 3</label><caption>
<title>Evolutionary relationships of patient D's viral population through time.</title>
<p>Each phylogeny shows the predicted R5 and CXCR4-using variants for the time points: screening, day 1, week 2, week 12 and week 16; only unique variants are shown. Subsequent to screening, the CXCR4-using variants from the previous time point are included for visualization purposes. Sequence logos for R5 and CXCR4-using sequences for each time point are also shown. Colors (see key) indicate sampling time in phylogenies and residue charges in sequence logos. The red numbers on the lineage separating branches at screening and day 1 indicate the branch support value from the <italic>approximate likelihood ratio test</italic> for the distinct CXCR4-using lineage present at these time points. The inset plots indicate the extent of the clustering present for these same lineages and time points (value next to circle on x axis) in comparison to a distribution of randomly assigned clusters; see methods for further details. The scale bar represents nucleotide substitutions per site.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001022.g003" xlink:type="simple"/></fig><fig id="pcbi-1001022-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001022.g004</object-id><label>Figure 4</label><caption>
<title>Evolutionary relationships of patient E's viral population through time.</title>
<p>Each phylogeny shows the predicted R5 and CXCR4-using variants for the time points: screening, day 1, week 8, week 24 and week 30. See <xref ref-type="fig" rid="pcbi-1001022-g003">figure 3</xref>'s legend for further details.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001022.g004" xlink:type="simple"/></fig>
<p>For each patient for the two time points prior to therapy when the CXCR4-using variants located within the R5 tropic clusters were investigated, they were observed to be more similar to their closely related R5 tropic counterparts than to the distinct clusters of CXCR4-using variants (<xref ref-type="fig" rid="pcbi-1001022-g003">Fig. 3</xref> and <xref ref-type="fig" rid="pcbi-1001022-g004">4</xref>, screening and Day 1). For patient D there are four such variants (1.1% of the CXCR4-using population), while for patient E there are ten (7% of the CXCR4-using population) prior to therapy.</p>
<p>It is important to note, the extent of the divergence in the phylogenetic trees is mainly due to the high number of either unique or rare variants. These variants cluster around high frequency variants within the population (<xref ref-type="fig" rid="pcbi-1001022-g005">Fig. 5</xref>). For example, at screening (Patient D) only ten variants make up 75% of the viral population with a single variant contributing to 23% of the population. Despite a proportion of this variation being due to sequencing error, this level of variation emerging in relatively short time periods highlights the extreme mutability of HIV.</p>
<fig id="pcbi-1001022-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001022.g005</object-id><label>Figure 5</label><caption>
<title>Frequency of HIV-1 variants in the phylogenetic trees.</title>
<p>Evolutionary tree inferred from all patient D's V3 nucleotide sequences (A), and all patient E's V3 nucleotide sequences (B). Colors (see key) indicate the frequency of each sequence. The scale bar represents nucleotide substitutions per site.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001022.g005" xlink:type="simple"/></fig>
<p><xref ref-type="table" rid="pcbi-1001022-t003">Tables 3</xref> and <xref ref-type="table" rid="pcbi-1001022-t004">4</xref> show the results of the PSSM test carried out on the extracted V3 sequences. In all cases, with the exception of patient E (week 8), PSSM confirms similar levels of CXCR4-using virus to those predicted by the charge rule. PSSM predicts viruses to be CXCR4-using based on scores being higher than a threshold of −2.88 (<xref ref-type="fig" rid="pcbi-1001022-g006">Fig. 6</xref>), and to be R5 tropic based on scores being below a threshold value of −6.96 (<xref ref-type="fig" rid="pcbi-1001022-g006">Fig. 6</xref>). Between these two threshold values a reliable PSSM prediction cannot be made and so composite PSSM utilizes the charge rule at sites 11 and 25 <xref ref-type="bibr" rid="pcbi.1001022-Jensen1">[24]</xref>. Note, we have also included site 24 in the composite prediction <xref ref-type="bibr" rid="pcbi.1001022-Cardozo1">[23]</xref>.</p>
<fig id="pcbi-1001022-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001022.g006</object-id><label>Figure 6</label><caption>
<title>Tropism prediction.</title>
<p>Frequency plots of PSSM scores of unique V3 sequences within each dataset. The red area indicates the region below the −6.96 threshold (R5), the green region indicates the area above the −2.88 threshold (CXCR4-using) and the grey area indicates the region between the two thresholds. The numbers within each plot area indicate the percentage of reads called as R5 or CXCR4-using for that region.</p>
</caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001022.g006" xlink:type="simple"/></fig></sec></sec><sec id="s4">
<title>Discussion</title>
<p>We have developed freely available software for the management and downstream analysis of pathogen sequence data. We demonstrate the utility of this software by applying it to the detection, and subsequent evolutionary analysis, of drug resistant variants within two temporally sampled patients infected with HIV-1. In our study of the V3 region we demonstrate that both the CXCR4-using viral populations, which emerge during maraviroc treatment, do not evolve <italic>de novo</italic>. Instead, confirming previous studies <xref ref-type="bibr" rid="pcbi.1001022-Archer1">[6]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Tsibris1">[11]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Westby1">[41]</xref>, they emerge from a pre-existing, distinct, viral subpopulation that is present prior to therapy (<xref ref-type="fig" rid="pcbi-1001022-g003">Fig. 3</xref> and <xref ref-type="fig" rid="pcbi-1001022-g004">4</xref>). Note, the phylogenetic analysis was repeated excluding sites 11, 24 and 25 (those used in the charge rule test), and the same divergent CXCR4-using cluster identified (and statistically supported), indicating convergent evolution is not biasing the inferences. If the R5 variants had evolved during treatment to become CXCR4-using they would be more closely related to these R5 counterparts. In addition, characteristic differences between R5 and X4 variants (specifically at sites 11, 24 or 25 in V3) are observed at screening and day 1 (<xref ref-type="fig" rid="pcbi-1001022-g003">Fig. 3</xref> and <xref ref-type="fig" rid="pcbi-1001022-g004">4</xref>, sequence logos).</p>
<p>We quantified the effects of HIV-1 mutability on the k-mer mapping process prior to downstream analysis. Using the patient D screening dataset, in conjunction with the consensus template for that data within which random mutations were introduced in sequential steps, we observed that at a divergence level of 26% just over 20% of the reads originally mapped to the unaltered consensus map successfully (<xref ref-type="fig" rid="pcbi-1001022-g002">Fig. 2</xref>). This demonstrates there is a direct relationship between the number of reads that are mapped successfully and the level of divergence between the data and template sequence. The usage of an inappropriate template will, thus, very probably result in the non-random loss of data, introducing an unnecessary bias. Indeed for each of our datasets, when mapped to HXB2 rather than the data-specific consensus templates, between 24 and 44% of reads covering the V3 region were not mapped as a result of divergence between the consensus templates and HXB2 which ranged form 14 to16.5% (<xref ref-type="table" rid="pcbi-1001022-t001">Table 1</xref>).</p>
<p>When an amino acid translation step is performed, in our case for inferring reads as R5 or CXCR4-using, data loss can be further minimized by utilizing a correction procedure relative to the in-frame template sequence. Platform-dependent insertions make up the majority of sequencing error usually resulting in an over-representation of frame shifts within the reads <xref ref-type="bibr" rid="pcbi.1001022-Brockman1">[2]</xref>, <xref ref-type="bibr" rid="pcbi.1001022-Wang1">[3]</xref>. Correction based on a divergent template will result in a greater probability of complete codons being removed erroneously and therefore it is optimal to use a template that is dataset specific (<xref ref-type="supplementary-material" rid="pcbi.1001022.s001">Figure S1</xref>). In Tsibris <italic>et al.</italic>, <xref ref-type="bibr" rid="pcbi.1001022-Tsibris1">[11]</xref> where no such correction was performed on temporally sampled data from two subtype B infected patients much of the data was removed. Within one sample a platform dependent insertion within a known homopolymeric stretch resulted in the staggering removal of 85% reads. Using a correction approach, based on an in-frame consensus template, reduces this loss greatly (<xref ref-type="table" rid="pcbi-1001022-t005">Table 5</xref>).</p>
<table-wrap id="pcbi-1001022-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1001022.t005</object-id><label>Table 5</label><caption>
<title>Reference template comparison.</title>
</caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1001022-t005-5" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001022.t005" xlink:type="simple"/><table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" colspan="2" rowspan="1"/>
<td align="left" colspan="2" rowspan="1">No reading frame correction</td>
<td align="left" colspan="2" rowspan="1">Data-specific consensus based frame correction</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Sample ID</td>
<td align="left" colspan="1" rowspan="1">No. of Reads</td>
<td align="left" colspan="1" rowspan="1">No. V3's</td>
<td align="left" colspan="1" rowspan="1">No. of V3's used after translation</td>
<td align="left" colspan="1" rowspan="1">No. V3's</td>
<td align="left" colspan="1" rowspan="1">No. of V3's used after translation</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>18.00</bold></td>
<td align="left" colspan="1" rowspan="1">138,681</td>
<td align="left" colspan="1" rowspan="1">130,268</td>
<td align="left" colspan="1" rowspan="1">110,471 (80%)</td>
<td align="left" colspan="1" rowspan="1">138,363</td>
<td align="left" colspan="1" rowspan="1">132,197 (95%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>18.02</bold></td>
<td align="left" colspan="1" rowspan="1">62,475</td>
<td align="left" colspan="1" rowspan="1">52,403</td>
<td align="left" colspan="1" rowspan="1">25,419 (41%)</td>
<td align="left" colspan="1" rowspan="1">61,747</td>
<td align="left" colspan="1" rowspan="1">54,558 (87%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>18.16</bold></td>
<td align="left" colspan="1" rowspan="1">98,025</td>
<td align="left" colspan="1" rowspan="1">86,392</td>
<td align="left" colspan="1" rowspan="1">14,366 (15%)</td>
<td align="left" colspan="1" rowspan="1">97,374</td>
<td align="left" colspan="1" rowspan="1">73,862 (75%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>19.00</bold></td>
<td align="left" colspan="1" rowspan="1">70,391</td>
<td align="left" colspan="1" rowspan="1">64,978</td>
<td align="left" colspan="1" rowspan="1">59,226 (84%)</td>
<td align="left" colspan="1" rowspan="1">69,937</td>
<td align="left" colspan="1" rowspan="1">66,655 (95%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>19.02</bold></td>
<td align="left" colspan="1" rowspan="1">46,826</td>
<td align="left" colspan="1" rowspan="1">43,224</td>
<td align="left" colspan="1" rowspan="1">38,217 (82%)</td>
<td align="left" colspan="1" rowspan="1">46,563</td>
<td align="left" colspan="1" rowspan="1">43,982 (94%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><bold>19.17</bold></td>
<td align="left" colspan="1" rowspan="1">25,685</td>
<td align="left" colspan="1" rowspan="1">23,755</td>
<td align="left" colspan="1" rowspan="1">22,519 (88%)</td>
<td align="left" colspan="1" rowspan="1">25,483</td>
<td align="left" colspan="1" rowspan="1">24,384 (95%)</td>
</tr>
</tbody>
</table></alternatives><table-wrap-foot><fn id="nt105"><label/><p>Comparison of use of a data-specific template with a published study which used HXB2 as a reference template <xref ref-type="bibr" rid="pcbi.1001022-Tsibris1">[11]</xref>. Dataset sizes are from Tsibris <italic>et al.</italic>, <xref ref-type="bibr" rid="pcbi.1001022-Tsibris1">[11]</xref>. The number of in-frame reads available for downstream analysis after correction based on a data-specific consensus is compared to the number of in-frame reads when no correction is applied.</p></fn></table-wrap-foot></table-wrap>
<p>Algorithms for the computational prediction of tropism are highly dependent on the available training datasets. In the case of PSSM, for example, the training data used in the web tool defines the threshold cutoff values (−2.88 and −6.96) used in the coreceptor prediction <xref ref-type="bibr" rid="pcbi.1001022-Jensen1">[24]</xref>. When data falls between the current threshold values the PSSM web tool uses the charge rule <xref ref-type="bibr" rid="pcbi.1001022-Jensen1">[24]</xref>. This can be misleading as seen for patient E week 8 (<xref ref-type="fig" rid="pcbi-1001022-g006">Fig. 6</xref>), the charge rule called 99.3% of the population as CXCR4-using based on the presence of a positive charge at site 25, while PSSM called 39.1% of the population as CXCR4-using (<xref ref-type="table" rid="pcbi-1001022-t004">Table 4</xref>). For the latter only 0.3% of variants fall above the PSSM CXCR4-using threshold. The remaining 38.8% of CXCR4-using variants is based on the charge rule and not the PSSM scores. The variants that fall below the CCR5-using threshold (60.9%), despite the majority still possessing a positively charged residue at site 25, have been called based on their PSSM scores. The most likely explanation is that these variants are dual tropic and typing them as R5 is incorrect.</p>
<p>It is also important to consider how much CXCR4-using virus is acceptable in the context of combination therapy. At present a 2% threshold has been proposed by RH <xref ref-type="bibr" rid="pcbi.1001022-Swenson1">[42]</xref>. In our study both patients had greater than 2% CXCR4-using virus at screening and the CXCR4-using population was greater than 10,000 copies/ml. Interestingly, although the CXCR4-using virus is clearly present during therapy, the overall CXCR4-using plasma HIV-1 RNA was reduced during the treatment phase, presumably due to the effect of the other drugs used with maraviroc.</p>
<p>In conclusion, our results demonstrate that, in conjunction with appropriate software, pyrosequencing data has utility for the evolutionally analysis and detection of low frequency variants within viral populations. In our analysis we have provided a high-resolution snapshot, through temporally sampled data, of intra-patient viral diversity and evolution associated with the CCR5-antagonist maraviroc. We have also quantified the effects of viral diversity on the initial k-mer mapping of read data in relation to the correction of platform dependent insertion error. The features of the software used here can be applied to other drug susceptibility and resistance studies, within other genomic regions of HIV-1 or to other pathogen genomes.</p>
</sec><sec id="s5">
<title>Supporting Information</title>
<supplementary-material id="pcbi.1001022.s001" mimetype="application/postscript" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1001022.s001" xlink:type="simple"><label>Figure S1</label><caption>
<p>Example of frame correction to a dataset specific template and HXB2. Pairwise alignment of the V3 region of the consensus template (patient D, screening) to that of HXB2 (A). Correction of the V3 sequence based on HXB2, and subsequent loss of a complete codon (B). Correction of the V3 sequence based on the data-specific template, and no codon loss (C).</p>
<p>(0.46 MB EPS)</p>
</caption></supplementary-material></sec></body>
<back><ref-list>
<title>References</title>
<ref id="pcbi.1001022-Margulies1"><label>1</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Margulies</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Egholm</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Altman</surname><given-names>WE</given-names></name>
<name name-style="western"><surname>Attiya</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Bader</surname><given-names>JS</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Genome sequencing in microfabricated high-density picolitre reactors.</article-title>             <source>Nature</source>             <volume>437</volume>             <fpage>376</fpage>             <lpage>380</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Brockman1"><label>2</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Brockman</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Alvarez</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Young</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Garber</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Giannoukos</surname><given-names>G</given-names></name>
<etal/></person-group>             <year>2008</year>             <article-title>Quality scores and SNP detection in sequencing-by-synthesis systems.</article-title>             <source>Genome Res</source>             <volume>18</volume>             <fpage>763</fpage>             <lpage>770</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Wang1"><label>3</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Wang</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Mitsuya</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Gharizadeh</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Ronaghi</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Shafer</surname><given-names>RW</given-names></name>
</person-group>             <year>2007</year>             <article-title>Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance.</article-title>             <source>Genome Res</source>             <volume>17</volume>             <fpage>1195</fpage>             <lpage>1201</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Pop1"><label>4</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Pop</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Salzberg</surname><given-names>SL</given-names></name>
</person-group>             <year>2008</year>             <article-title>Bioinformatics challenges of new sequencing technology.</article-title>             <source>Trends Genet</source>             <volume>24</volume>             <fpage>142</fpage>             <lpage>149</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Shendure1"><label>5</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Shendure</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Hanlee</surname><given-names>J</given-names></name>
</person-group>             <year>2008</year>             <article-title>Next-generation DNA sequencing.</article-title>             <source>Nat Biotech</source>             <volume>26</volume>             <fpage>1135</fpage>             <lpage>1145</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Archer1"><label>6</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Archer</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Braverman</surname><given-names>MS</given-names></name>
<name name-style="western"><surname>Taillon</surname><given-names>BE</given-names></name>
<name name-style="western"><surname>Desany</surname><given-names>B</given-names></name>
<name name-style="western"><surname>James</surname><given-names>I</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing.</article-title>             <source>AIDS</source>             <volume>23</volume>             <fpage>1209</fpage>             <lpage>1218</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Bruselles1"><label>7</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Bruselles</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Rozera</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Bartolini</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Prosperi</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Del Nonno</surname><given-names>F</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Use of massive parallel pyrosequencing for near full-length characterization of a unique HIV Type 1 BF recombinant associated with a fatal primary infection.</article-title>             <source>AIDS Res Hum Retroviruses</source>             <volume>25</volume>             <fpage>937</fpage>             <lpage>942</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Le1"><label>8</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Le</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Chiarella</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Simen</surname><given-names>BB</given-names></name>
<name name-style="western"><surname>Hanczaruk</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Egholm</surname><given-names>M</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use.</article-title>             <source>PLoS One</source>             <volume>4</volume>             <fpage>e6079</fpage>          </element-citation></ref>
<ref id="pcbi.1001022-Palmer1"><label>9</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Palmer</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Kearney</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Maldarelli</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Halvas</surname><given-names>EK</given-names></name>
<name name-style="western"><surname>Bixby</surname><given-names>CJ</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.</article-title>             <source>J Clin Microbiol</source>             <volume>43</volume>             <fpage>406</fpage>             <lpage>413</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Rozera1"><label>10</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Rozera</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Abbate</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Bruselles</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Vlassi</surname><given-names>C</given-names></name>
<name name-style="western"><surname>D'Offizi</surname><given-names>G</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations.</article-title>             <source>Retrovirology</source>             <volume>6</volume>             <fpage>15</fpage>          </element-citation></ref>
<ref id="pcbi.1001022-Tsibris1"><label>11</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Tsibris</surname><given-names>AM</given-names></name>
<name name-style="western"><surname>Korber</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Arnaout</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Russ</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Lo</surname><given-names>CC</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.</article-title>             <source>PLoS One</source>             <volume>4</volume>             <fpage>e5683</fpage>          </element-citation></ref>
<ref id="pcbi.1001022-Li1"><label>12</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Li</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Ruan</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Durbin</surname><given-names>R</given-names></name>
</person-group>             <year>2008</year>             <article-title>Mapping short DNA sequencing reads and calling variants using mapping quality scores.</article-title>             <source>Genome Res</source>             <volume>18</volume>             <fpage>1851</fpage>             <lpage>1858</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Altschul1"><label>13</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Altschul</surname><given-names>SF</given-names></name>
<name name-style="western"><surname>Madden</surname><given-names>TL</given-names></name>
<name name-style="western"><surname>Schaffer</surname><given-names>AA</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name>
<etal/></person-group>             <year>1997</year>             <article-title>Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.</article-title>             <source>Nucleic Acids Res</source>             <volume>25</volume>             <fpage>3389</fpage>             <lpage>3402</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Buhler1"><label>14</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Buhler</surname><given-names>J</given-names></name>
</person-group>             <year>2001</year>             <article-title>Efficient large-scale sequence comparison by locality-sensitive hashing.</article-title>             <source>Bioinformatics</source>             <volume>17</volume>             <fpage>419</fpage>             <lpage>428</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Kent1"><label>15</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Kent</surname><given-names>WJ</given-names></name>
</person-group>             <year>2002</year>             <article-title>BLAT–the BLAST-like alignment tool.</article-title>             <source>Genome Res</source>             <volume>12</volume>             <fpage>656</fpage>             <lpage>664</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Homer1"><label>16</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Homer</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Merriman</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Nelson</surname><given-names>SF</given-names></name>
</person-group>             <year>2009</year>             <article-title>BFAST: an alignment tool for large scale genome resequencing.</article-title>             <source>PLoS One</source>             <volume>4</volume>             <fpage>e7767</fpage>          </element-citation></ref>
<ref id="pcbi.1001022-Langmead1"><label>17</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Langmead</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Trapnell</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Pop</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Salzberg</surname><given-names>SL</given-names></name>
</person-group>             <year>2009</year>             <article-title>Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.</article-title>             <source>Genome Biol</source>             <volume>10</volume>             <fpage>R25</fpage>          </element-citation></ref>
<ref id="pcbi.1001022-Rumble1"><label>18</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Rumble</surname><given-names>SM</given-names></name>
<name name-style="western"><surname>Lacroute</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Dalca</surname><given-names>AV</given-names></name>
<name name-style="western"><surname>Fiume</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Sidow</surname><given-names>A</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>SHRiMP: accurate mapping of short color-space reads.</article-title>             <source>PLoS Comput Biol</source>             <volume>5</volume>             <fpage>e1000386</fpage>          </element-citation></ref>
<ref id="pcbi.1001022-Starcich1"><label>19</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Starcich</surname><given-names>BR</given-names></name>
<name name-style="western"><surname>Hahn</surname><given-names>BH</given-names></name>
<name name-style="western"><surname>Shaw</surname><given-names>GM</given-names></name>
<name name-style="western"><surname>McNeely</surname><given-names>PD</given-names></name>
<name name-style="western"><surname>Modrow</surname><given-names>S</given-names></name>
<etal/></person-group>             <year>1986</year>             <article-title>Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.</article-title>             <source>Cell</source>             <volume>45</volume>             <fpage>637</fpage>             <lpage>648</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Bjorndal1"><label>20</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Bjorndal</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Deng</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Jansson</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Fiore</surname><given-names>JR</given-names></name>
<name name-style="western"><surname>Colognesi</surname><given-names>C</given-names></name>
<etal/></person-group>             <year>1997</year>             <article-title>Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype.</article-title>             <source>J Virol</source>             <volume>71</volume>             <fpage>7478</fpage>             <lpage>7487</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Connor1"><label>21</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Connor</surname><given-names>RI</given-names></name>
<name name-style="western"><surname>Sheridan</surname><given-names>KE</given-names></name>
<name name-style="western"><surname>Ceradini</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Choe</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Landau</surname><given-names>NR</given-names></name>
</person-group>             <year>1997</year>             <article-title>Change in coreceptor use correlates with disease progression in HIV-1–infected individuals.</article-title>             <source>J Exp Med</source>             <volume>185</volume>             <fpage>621</fpage>             <lpage>628</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Koot1"><label>22</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Koot</surname><given-names>M</given-names></name>
<name name-style="western"><surname>van Leeuwen</surname><given-names>R</given-names></name>
<name name-style="western"><surname>de Goede</surname><given-names>RE</given-names></name>
<name name-style="western"><surname>Keet</surname><given-names>IP</given-names></name>
<name name-style="western"><surname>Danner</surname><given-names>S</given-names></name>
<etal/></person-group>             <year>1999</year>             <article-title>Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis.</article-title>             <source>J Infect Dis</source>             <volume>179</volume>             <fpage>254</fpage>             <lpage>258</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Cardozo1"><label>23</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Cardozo</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Kimura</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Philpott</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Weiser</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Burger</surname><given-names>H</given-names></name>
<etal/></person-group>             <year>2007</year>             <article-title>Structural basis for coreceptor selectivity by the HIV type 1 V3 loop.</article-title>             <source>AIDS Res Hum Retroviruses</source>             <volume>23</volume>             <fpage>415</fpage>             <lpage>426</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Jensen1"><label>24</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Jensen</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>FS</given-names></name>
<name name-style="western"><surname>van 't Wout</surname><given-names>AB</given-names></name>
<name name-style="western"><surname>Nickle</surname><given-names>DC</given-names></name>
<name name-style="western"><surname>Shriner</surname><given-names>D</given-names></name>
<etal/></person-group>             <year>2003</year>             <article-title>Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.</article-title>             <source>J Virol</source>             <volume>77</volume>             <fpage>13376</fpage>             <lpage>13388</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Soriano1"><label>25</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Soriano</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Perno</surname><given-names>CF</given-names></name>
<name name-style="western"><surname>Kaiser</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Calvez</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Gatell</surname><given-names>JM</given-names></name>
<etal/></person-group>             <year>2009</year>             <article-title>When and how to use maraviroc in HIV-infected patients.</article-title>             <source>AIDS</source>             <volume>23</volume>             <fpage>2377</fpage>             <lpage>2385</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Jetzt1"><label>26</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Jetzt</surname><given-names>AE</given-names></name>
<name name-style="western"><surname>Yu</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Klarmann</surname><given-names>GJ</given-names></name>
<name name-style="western"><surname>Ron</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Preston</surname><given-names>BD</given-names></name>
<etal/></person-group>             <year>2000</year>             <article-title>High rate of recombination throughout the human immunodeficiency virus type 1 genome.</article-title>             <source>J Virol</source>             <volume>74</volume>             <fpage>1234</fpage>             <lpage>1240</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Korber1"><label>27</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Korber</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Gaschen</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Yusim</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Thakallapally</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Kesmir</surname><given-names>C</given-names></name>
<etal/></person-group>             <year>2001</year>             <article-title>Evolutionary and immunological implications of contemporary HIV-1 variation.</article-title>             <source>Br Med Bull</source>             <volume>58</volume>             <fpage>19</fpage>             <lpage>42</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Malim1"><label>28</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Malim</surname><given-names>MH</given-names></name>
<name name-style="western"><surname>Emerman</surname><given-names>M</given-names></name>
</person-group>             <year>2001</year>             <article-title>HIV-1 sequence variation: drift, shift, and attenuation.</article-title>             <source>Cell</source>             <volume>104</volume>             <fpage>469</fpage>             <lpage>472</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Wei1"><label>29</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Wei</surname><given-names>X</given-names></name>
<name name-style="western"><surname>Ghosh</surname><given-names>SK</given-names></name>
<name name-style="western"><surname>Taylor</surname><given-names>ME</given-names></name>
<name name-style="western"><surname>Johnson</surname><given-names>VA</given-names></name>
<name name-style="western"><surname>Emini</surname><given-names>EA</given-names></name>
<etal/></person-group>             <year>1995</year>             <article-title>Viral dynamics in human immunodeficiency virus type 1 infection.</article-title>             <source>Nature</source>             <volume>373</volume>             <fpage>117</fpage>             <lpage>122</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Dorr1"><label>30</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Dorr</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Westby</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Dobbs</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Griffin</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Irvine</surname><given-names>B</given-names></name>
<etal/></person-group>             <year>2005</year>             <article-title>Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.</article-title>             <source>Antimicrob Agents Chemother</source>             <volume>49</volume>             <fpage>4721</fpage>             <lpage>4732</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Cooper1"><label>31</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Cooper</surname><given-names>DA</given-names></name>
<name name-style="western"><surname>Heera</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Goodrich</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Tawadrous</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Saag</surname><given-names>M</given-names></name>
<etal/></person-group>             <year>2010</year>             <article-title>Maraviroc versus Efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.</article-title>             <source>J Infect Dis</source>             <volume>201</volume>             <fpage>803</fpage>             <lpage>813</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Rosen1"><label>32</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Rosen</surname><given-names>O</given-names></name>
<name name-style="western"><surname>Sharon</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Quadt-Akabayov</surname><given-names>SR</given-names></name>
<name name-style="western"><surname>Anglister</surname><given-names>J</given-names></name>
</person-group>             <year>2006</year>             <article-title>Molecular switch for alternative conformations of the HIV-1 V3 region: implications for phenotype conversion.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>103</volume>             <fpage>13950</fpage>             <lpage>13955</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Smith1"><label>33</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Smith</surname><given-names>TF</given-names></name>
<name name-style="western"><surname>Waterman</surname><given-names>MS</given-names></name>
</person-group>             <year>1981</year>             <article-title>Identification of common molecular subsequences.</article-title>             <source>J Mol Biol</source>             <volume>147</volume>             <fpage>195</fpage>             <lpage>197</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Edgar1"><label>34</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Edgar</surname><given-names>RC</given-names></name>
</person-group>             <year>2004</year>             <article-title>MUSCLE: multiple sequence alignment with high accuracy and high throughput.</article-title>             <source>Nucleic Acids Res</source>             <volume>32</volume>             <fpage>1792</fpage>             <lpage>1797</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Crooks1"><label>35</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Crooks</surname><given-names>GE</given-names></name>
<name name-style="western"><surname>Hon</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Chandonia</surname><given-names>JM</given-names></name>
<name name-style="western"><surname>Brenner</surname><given-names>SE</given-names></name>
</person-group>             <year>2004</year>             <article-title>WebLogo: a sequence logo generator.</article-title>             <source>Genome Res</source>             <volume>14</volume>             <fpage>1188</fpage>             <lpage>1190</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Guindon1"><label>36</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Guindon</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Gascuel</surname><given-names>O</given-names></name>
</person-group>             <year>2003</year>             <article-title>A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood.</article-title>             <source>Syst Biol</source>             <volume>52</volume>             <fpage>696</fpage>             <lpage>704</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Archer2"><label>37</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Archer</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Robertson</surname><given-names>DL</given-names></name>
</person-group>             <year>2007</year>             <article-title>CTree: comparison of clusters between phylogenetic trees made easy.</article-title>             <source>Bioinformatics</source>             <volume>23</volume>             <fpage>2952</fpage>             <lpage>2953</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Archer3"><label>38</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Archer</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Robertson</surname><given-names>DL</given-names></name>
</person-group>             <year>2007</year>             <article-title>Understanding the diversification of HIV-1 groups M and O.</article-title>             <source>Aids</source>             <volume>21</volume>             <fpage>1693</fpage>             <lpage>1700</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Rambaut1"><label>39</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Rambaut</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Robertson</surname><given-names>DL</given-names></name>
<name name-style="western"><surname>Pybus</surname><given-names>OG</given-names></name>
<name name-style="western"><surname>Peeters</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Holmes</surname><given-names>EC</given-names></name>
</person-group>             <year>2001</year>             <article-title>Human immunodeficiency virus. Phylogeny and the origin of HIV-1.</article-title>             <source>Nature</source>             <volume>410</volume>             <fpage>1047</fpage>             <lpage>1048</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Anisimova1"><label>40</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Anisimova</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Gascuel</surname><given-names>O</given-names></name>
</person-group>             <year>2006</year>             <article-title>Approximate likelihood-ratio test for branches: A fast, accurate, and powerful alternative.</article-title>             <source>Syst Biol</source>             <volume>55</volume>             <fpage>539</fpage>             <lpage>552</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Westby1"><label>41</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Westby</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Lewis</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Whitcomb</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Youle</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Pozniak</surname><given-names>AL</given-names></name>
<etal/></person-group>             <year>2006</year>             <article-title>Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.</article-title>             <source>J Virol</source>             <volume>80</volume>             <fpage>4909</fpage>             <lpage>4920</lpage>          </element-citation></ref>
<ref id="pcbi.1001022-Swenson1"><label>42</label><element-citation publication-type="journal" xlink:type="simple">             <person-group person-group-type="author">
<name name-style="western"><surname>Swenson</surname><given-names>LC</given-names></name>
<name name-style="western"><surname>Moores</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Low</surname><given-names>AJ</given-names></name>
<name name-style="western"><surname>Thielen</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Dong</surname><given-names>W</given-names></name>
<etal/></person-group>             <year>2010</year>             <article-title>Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and “deep” sequencing to plasma RNA and proviral DNA.</article-title>             <source>J Acquir Immune Defic Syndr</source>             <volume>54</volume>             <fpage>506</fpage>             <lpage>510</lpage>          </element-citation></ref>
</ref-list>

</back>
</article>